PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2832191-0 1988 Evidence for a differential interaction of buprenorphine with opiate receptor subtypes controlling prolactin secretion. Buprenorphine 43-56 prolactin Homo sapiens 99-108 2723127-0 1989 Naloxone suppresses buprenorphine stimulation of plasma prolactin. Buprenorphine 20-33 prolactin Homo sapiens 56-65 2723127-3 1989 Simultaneous injection of buprenorphine 0.3 mg and saline resulted in an average increase in plasma prolactin above baseline levels of approximately 10 and 25 ng/ml, 30 and 55 minutes after injection. Buprenorphine 26-39 prolactin Homo sapiens 100-109 2723127-4 1989 Buprenorphine-induced stimulation of plasma prolactin levels was statistically significantly greater than basal prolactin values (p less than 0.01). Buprenorphine 0-13 prolactin Homo sapiens 44-53 2723127-5 1989 When 0.6 mg of naloxone was simultaneously injected with 0.3 mg buprenorphine, peak plasma prolactin levels were significantly lower (p less than 0.05) than prolactin values after administration of 0.3 mg buprenorphine and saline. Buprenorphine 64-77 prolactin Homo sapiens 91-100 2723127-6 1989 Simultaneous injection of 0.45 mg naloxone and 0.3 mg buprenorphine also resulted in a significant attenuation (p less than 0.05) of buprenorphine-stimulated prolactin levels. Buprenorphine 54-67 prolactin Homo sapiens 158-167 2723127-6 1989 Simultaneous injection of 0.45 mg naloxone and 0.3 mg buprenorphine also resulted in a significant attenuation (p less than 0.05) of buprenorphine-stimulated prolactin levels. Buprenorphine 133-146 prolactin Homo sapiens 158-167 2723127-8 1989 These findings demonstrate a dose-effect relationship between naloxone concentration and suppression of the increase in plasma prolactin levels produced by administration of buprenorphine 0.3 mg. As prolactin stimulation occurs shortly after opioid agonist administration and is temporally concordant with the rapid induction of pharmacologic reinforcement associated with opiate abuse, naloxone added to buprenorphine parenteral preparations may reduce the abuse potential of buprenorphine. Buprenorphine 174-187 prolactin Homo sapiens 127-136 2723127-8 1989 These findings demonstrate a dose-effect relationship between naloxone concentration and suppression of the increase in plasma prolactin levels produced by administration of buprenorphine 0.3 mg. As prolactin stimulation occurs shortly after opioid agonist administration and is temporally concordant with the rapid induction of pharmacologic reinforcement associated with opiate abuse, naloxone added to buprenorphine parenteral preparations may reduce the abuse potential of buprenorphine. Buprenorphine 174-187 prolactin Homo sapiens 199-208 2723127-8 1989 These findings demonstrate a dose-effect relationship between naloxone concentration and suppression of the increase in plasma prolactin levels produced by administration of buprenorphine 0.3 mg. As prolactin stimulation occurs shortly after opioid agonist administration and is temporally concordant with the rapid induction of pharmacologic reinforcement associated with opiate abuse, naloxone added to buprenorphine parenteral preparations may reduce the abuse potential of buprenorphine. Buprenorphine 405-418 prolactin Homo sapiens 127-136 2723127-8 1989 These findings demonstrate a dose-effect relationship between naloxone concentration and suppression of the increase in plasma prolactin levels produced by administration of buprenorphine 0.3 mg. As prolactin stimulation occurs shortly after opioid agonist administration and is temporally concordant with the rapid induction of pharmacologic reinforcement associated with opiate abuse, naloxone added to buprenorphine parenteral preparations may reduce the abuse potential of buprenorphine. Buprenorphine 405-418 prolactin Homo sapiens 199-208 2723127-8 1989 These findings demonstrate a dose-effect relationship between naloxone concentration and suppression of the increase in plasma prolactin levels produced by administration of buprenorphine 0.3 mg. As prolactin stimulation occurs shortly after opioid agonist administration and is temporally concordant with the rapid induction of pharmacologic reinforcement associated with opiate abuse, naloxone added to buprenorphine parenteral preparations may reduce the abuse potential of buprenorphine. Buprenorphine 405-418 prolactin Homo sapiens 127-136 2723127-8 1989 These findings demonstrate a dose-effect relationship between naloxone concentration and suppression of the increase in plasma prolactin levels produced by administration of buprenorphine 0.3 mg. As prolactin stimulation occurs shortly after opioid agonist administration and is temporally concordant with the rapid induction of pharmacologic reinforcement associated with opiate abuse, naloxone added to buprenorphine parenteral preparations may reduce the abuse potential of buprenorphine. Buprenorphine 405-418 prolactin Homo sapiens 199-208 2832191-1 1988 We studied the effects of various doses of the opiate derivative buprenorphine on serum prolactin levels and whether these effects could be counteracted by pretreatment with the opiate receptor blocker naloxone. Buprenorphine 65-78 prolactin Homo sapiens 88-97 2832191-2 1988 The administration of increasing doses of buprenorphine exerted a dual effect on serum prolactin levels. Buprenorphine 42-55 prolactin Homo sapiens 87-96 2832191-6 1988 These data are compatible with the hypothesis that buprenorphine could interfere with two different, but inter-dependent receptors: at low doses the oripavine derivative could act at one receptor site to cause an increase of serum prolactin, whereas at higher doses it could interact with a second site of lower affinity that is responsible for the inhibition of prolactin secretion. Buprenorphine 51-64 prolactin Homo sapiens 231-240 2832191-6 1988 These data are compatible with the hypothesis that buprenorphine could interfere with two different, but inter-dependent receptors: at low doses the oripavine derivative could act at one receptor site to cause an increase of serum prolactin, whereas at higher doses it could interact with a second site of lower affinity that is responsible for the inhibition of prolactin secretion. Buprenorphine 51-64 prolactin Homo sapiens 363-372 7057390-0 1982 Buprenorphine effects on plasma luteinizing hormone and prolactin in male heroin addicts. Buprenorphine 0-13 prolactin Homo sapiens 56-65 7057390-1 1982 Buprenorphine, a mixed opiate agonist-antagonist, suppressed plasma luteinizing hormone (LH) and increased prolactin levels after 12 consecutive days of ascending dose administration (0.5-8 mg/day s.c.) in comparison to drug-free control conditions. Buprenorphine 0-13 prolactin Homo sapiens 107-116 7057390-2 1982 During a subsequent 10-day period of buprenorphine maintenance at a dose of a 8 mg s.c., LH levels remained suppressed and prolactin levels continued to be elevated. Buprenorphine 37-50 prolactin Homo sapiens 123-132 7057390-3 1982 Tolerance to buprenorphine effects on LH and prolactin levels did not occur during chronic drug administration. Buprenorphine 13-26 prolactin Homo sapiens 45-54 7057390-4 1982 Buprenorphine-induced changes in plasma LH and prolactin after chronic administration to human males were smaller than those observed with less potent opiate agonist drugs. Buprenorphine 0-13 prolactin Homo sapiens 47-56 7057390-5 1982 Effects of buprenorphine on LH and prolactin levels are more consistent with the actions of opiate agonists rather than opiate antagonists. Buprenorphine 11-24 prolactin Homo sapiens 35-44